A dark week, but here are four pieces of good news on the COVID-front.
1) There's a growing consensus that COVID reinfection is unlikely. Immunity probably doesn't disappear after a few weeks, or months. For more on how COVID immunity works:
theatlantic.com/ideas/archive/…
1) There's a growing consensus that COVID reinfection is unlikely. Immunity probably doesn't disappear after a few weeks, or months. For more on how COVID immunity works:
theatlantic.com/ideas/archive/…
2) Transmission of COVID-19 from mothers to newborns is unlikely to occur with basic hygiene precautions.
.
.
3) Modelers are projecting that total new infections have peaked.
We can see that case growth has already peaked in hotspot states, led by a 33 percent decline from peak in Arizona.
We can see that case growth has already peaked in hotspot states, led by a 33 percent decline from peak in Arizona.
4) Hospital mortality rate has declined significantly since April. One reason is that we've discovered new effective drugs (no, not hydroxychloroquine.
nature.com/articles/s4158…
New research has identified 13 more FDA-approved anti-viral candidates.
nature.com/articles/s4158…
New research has identified 13 more FDA-approved anti-viral candidates.
Big picture: This summer's COVID surge has been a catastrophic unforced error, and deaths are rising again. There's little to celebrate here, but perhaps some reasons to hope that, with continued vigilance and bit of government competence, we can bend this curve.
